Screener
G&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Costs and expenses * | ||||
| Cost of sales ** | $43,595 | $48,881 | $86,093 | $91,595 |
| Research and development ** | 58,851 | 77,928 | 121,338 | 153,895 |
| Selling, general, and administrative ** | 39,272 | 37,567 | 78,221 | 81,366 |
| Depreciation and amortization | 9,500 | 9,350 | 18,039 | 17,415 |
| Total costs and expenses | $151,218 | $173,726 | $303,691 | $344,271 |
| Loss from operations | (51,905) | (113,774) | (132,948) | (234,995) |
| Other income |
Item 1.Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Iovance Biotherapeutics, Inc.'s G&A?
- Iovance Biotherapeutics, Inc. (IOVA) reported G&A of $39.27M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s G&A changed year-over-year?
- Iovance Biotherapeutics, Inc.'s G&A increased by 4.5% year-over-year, from $37.57M to $39.27M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s G&A?
- Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s G&A has grown at a 16.2% compound annual growth rate (CAGR), from $83.66M to $152.32M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Iovance Biotherapeutics, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude